ggGGACGACGTCGTGgggggG ODN 2336 SEQ ID NO:37,
wherein each lower case letter represents phosphorothioate linkage and each upper case letter indicates phosphodiester linkage; and

a pharmaceutically acceptable carrier.

In the Specification

1. Please enter the Substitute Paper Copy and Substitute Computer Readable Form (CRF) Sequence Listing, along with the Statement Under 37 C.F.R. § 1.825, mailed together under separate cover, concurrent with the mailing of this Amendment, to United States Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202.

2. Please delete the paragraph beginning at line 22 on page 68 and replace it with the following paragraph:

CD8+ T cells (1×10^6) from HLA A2 positive healthy donors were stimulated in 24 well plates in the presence or absence of CpG ODN 2006 (SEQ ID NO:147), 1585 (SEQ ID NO:1), or 2216 (SEQ ID NO:7) at 6 μg/ml with either a HLA A2-restricted peptide derived from the influenza matrix protein (GILGFVFTL; SEQ ID NO:166) or a peptide derived from the melan A/mart-1 protein (ELAGIGILTV; SEQ ID NO:167). Autologous PBMC (3×10^6) were used as APCs. After 14 days cells were harvested, washed, and restimulated with influenza matrix or melan-A peptides for 6 hours. Brefeldin A was added for the last 4 hours. Cells were stained for CD8 and CD3, subsequently fixed, permeabilized and stained with mAb against IFN-γ. Also after 14 days the percentage of tetramer-positive $CD8^+$ T cells (HLA-A2/melan-A-peptide and HLA-A2/influenza matrix-peptide) was determined by flow cytometry. Tetramers are fluorochrome-labeled MHC-peptide tetramers which are designed to bind specifically to a peptide-specific T cell receptor, making it possible to identify peptide-specific T cells using flow cytometry. Altman JD et al. *Science* 274:94-96 (1996); U.S. Patent No. 5,635,363.